Jan Hartmann: New Transformative Treatment for Hemophilia A
Jan Hartmann, Senior Vice President, Chief Medical Officer at Haemonetics, shared a post on LinkedIn:
”Congratulations to the team led by Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa of Chugai Pharmaceutical Co., Ltd. on being awarded the 2026 Lasker-DeBakey Clinical Medical Research Award for their pioneering development of a bispecific antibody that revolutionized the treatment of Hemophilia.
First approved in 2017 and subsequently licensed by Genentech, emicizumab (Hemlibra) provided a transformative new treatment option for people living with hemophilia A.
Beyond its impact on patient care, its success demonstrated the potential of bispecific antibodies as a therapeutic platform and helped catalyze the development of this modality across a wide range of diseases.”
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:39David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:34The Changing Landscape of Anticoagulant Therapy – ISTH
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters